Anna Zemczak1, Paweł Gut2, Dariusz Pawlak3, Maciej Kołodziej4, Leszek Królicki5, Beata Kos-Kudła1, Marek Ruchała2, Grzegorz Kamiński4, Jolanta Kunikowska5. 1. Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland. 2. Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland. 3. Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland. 4. Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland. 5. Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland.
Abstract
PURPOSE: The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs). The study aims to evaluate the safety, efficacy, and progression-free survival (PFS) of patients after retreatment (R-PRRT) and re-retreatment (RR-PRRT) with tandem isotopes [90Y]Y/[177Lu]Lu-DOTATATE. Material and Methods. Out of 99 treated patients with G1 and G2 NETs, 26 were included in the study and treated with the repeated PRRT (with 5 undergoing the re-repeated PRRT treatment) after an initial positive response to four PRRT cycles and later progression of the disease. [68Ga]Ga-DOTATATE PET/CT and CT/MRI procedures were performed before and after the treatment. Patients were treated with [90Y]Y/[177Lu]Lu-DOTATATE (1 : 1) with mixed amino acid infusion for kidney protection. Toxicity was evaluated using the CTCAE 3.0 criteria. RESULTS: The median follow-up was 88 months (the range: 42-164). The median cumulative administered activity was 22.2 GBq (the range: 17.8-30.7 GBq). Myelodysplastic syndrome occurred in one patient (3.8%), and grade 4 renal toxicity was also detected in one patient (3.8%). No other cases of grade 3 or 4 bone marrow and renal toxicity were observed. The median PFS rate was 31 months after the PRRT and 23 months following the R-PRRT. The OS rate from the diagnosis (OS-d) was 109 months and from the start of the PRRT (OS-t)-92.4 months. During the restaging, 3-6 months after the PRRT, PR, SD, and PD were observed in 19.2%, 80.8%, and 0% of the patients, respectively. After the R-PRRT, PR, SD, and PD were observed in 50%, 42.3%, and 7.7% of the patients, respectively. CONCLUSIONS: The repeated therapy with [90Y]Y/[177Lu]Lu-DOTATATE is safe and effective for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours.
PURPOSE: The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs). The study aims to evaluate the safety, efficacy, and progression-free survival (PFS) of patients after retreatment (R-PRRT) and re-retreatment (RR-PRRT) with tandem isotopes [90Y]Y/[177Lu]Lu-DOTATATE. Material and Methods. Out of 99 treated patients with G1 and G2 NETs, 26 were included in the study and treated with the repeated PRRT (with 5 undergoing the re-repeated PRRT treatment) after an initial positive response to four PRRT cycles and later progression of the disease. [68Ga]Ga-DOTATATE PET/CT and CT/MRI procedures were performed before and after the treatment. Patients were treated with [90Y]Y/[177Lu]Lu-DOTATATE (1 : 1) with mixed amino acid infusion for kidney protection. Toxicity was evaluated using the CTCAE 3.0 criteria. RESULTS: The median follow-up was 88 months (the range: 42-164). The median cumulative administered activity was 22.2 GBq (the range: 17.8-30.7 GBq). Myelodysplastic syndrome occurred in one patient (3.8%), and grade 4 renal toxicity was also detected in one patient (3.8%). No other cases of grade 3 or 4 bone marrow and renal toxicity were observed. The median PFS rate was 31 months after the PRRT and 23 months following the R-PRRT. The OS rate from the diagnosis (OS-d) was 109 months and from the start of the PRRT (OS-t)-92.4 months. During the restaging, 3-6 months after the PRRT, PR, SD, and PD were observed in 19.2%, 80.8%, and 0% of the patients, respectively. After the R-PRRT, PR, SD, and PD were observed in 50%, 42.3%, and 7.7% of the patients, respectively. CONCLUSIONS: The repeated therapy with [90Y]Y/[177Lu]Lu-DOTATATE is safe and effective for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours.
Authors: Anastassia Löser; Sarah M Schwarzenböck; Martin Heuschkel; Holger S Willenberg; Bernd J Krause; Jens Kurth Journal: Nucl Med Commun Date: 2018-03 Impact factor: 1.690
Authors: Dik J Kwekkeboom; Jan Mueller-Brand; Giovanni Paganelli; Lowell B Anthony; Stanislas Pauwels; Larry K Kvols; Thomas M O'dorisio; Roelf Valkema; Lisa Bodei; Marco Chinol; Helmut R Maecke; Eric P Krenning Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057
Authors: Dik J Kwekkeboom; Boen L Kam; Martijn van Essen; Jaap J M Teunissen; Casper H J van Eijck; Roelf Valkema; Marion de Jong; Wouter W de Herder; Eric P Krenning Journal: Endocr Relat Cancer Date: 2010-01-29 Impact factor: 5.678
Authors: Anna Zemczak; Maciej Kołodziej; Paweł Gut; Leszek Królicki; Beata Kos-Kudła; Grzegorz Kamiński; Marek Ruchała; Dariusz Pawlak; Jolanta Kunikowska Journal: Endokrynol Pol Date: 2020-04-15 Impact factor: 1.582
Authors: L Bodei; D Ferone; C M Grana; M Cremonesi; A Signore; R A Dierckx; G Paganelli Journal: J Endocrinol Invest Date: 2009-04 Impact factor: 4.256
Authors: S Rudisile; A Gosewisch; V Wenter; M Unterrainer; G Böning; F J Gildehaus; W P Fendler; C J Auernhammer; C Spitzweg; P Bartenstein; A Todica; H Ilhan Journal: BMC Cancer Date: 2019-08-08 Impact factor: 4.430